- Home
- PLMR vs CELC Comparison
PLMR vs CELC Comparison
Compare PLMR & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLMR
- CELC
- Stock Information
- Founded
- PLMR 2013
- CELC 2011
- Country
- PLMR United States
- CELC United States
- Employees
- PLMR N/A
- CELC N/A
- Industry
- PLMR Property-Casualty Insurers
- CELC Medical Specialities
- Sector
- PLMR Finance
- CELC Health Care
- Exchange
- PLMR Nasdaq
- CELC Nasdaq
- Market Cap
- PLMR 3.0B
- CELC 3.1B
- IPO Year
- PLMR 2019
- CELC 2017
- Fundamental
- Price
- PLMR $128.52
- CELC $74.43
- Analyst Decision
- PLMR Buy
- CELC Strong Buy
- Analyst Count
- PLMR 8
- CELC 5
- Target Price
- PLMR $148.57
- CELC $69.40
- AVG Volume (30 Days)
- PLMR 248.7K
- CELC 1.4M
- Earning Date
- PLMR 11-06-2025
- CELC 11-12-2025
- Dividend Yield
- PLMR N/A
- CELC N/A
- EPS Growth
- PLMR 51.73
- CELC N/A
- EPS
- PLMR 6.40
- CELC N/A
- Revenue
- PLMR $778,362,000.00
- CELC N/A
- Revenue This Year
- PLMR $255.68
- CELC N/A
- Revenue Next Year
- PLMR $19.34
- CELC N/A
- P/E Ratio
- PLMR $20.00
- CELC N/A
- Revenue Growth
- PLMR 54.59
- CELC N/A
- 52 Week Low
- PLMR $94.45
- CELC $7.58
- 52 Week High
- PLMR $175.85
- CELC $83.00
- Technical
- Relative Strength Index (RSI)
- PLMR 71.52
- CELC 63.78
- Support Level
- PLMR $115.24
- CELC $71.06
- Resistance Level
- PLMR $115.12
- CELC $75.02
- Average True Range (ATR)
- PLMR 3.38
- CELC 4.43
- MACD
- PLMR 1.38
- CELC -0.15
- Stochastic Oscillator
- PLMR 90.51
- CELC 63.27
About PLMR Palomar Holdings Inc. Common stock
Palomar Holdings Inc that provides property and casualty insurance products to individuals and businesses. provide insurance products serving five categories: Earthquake, Inland Marine and Other Property, Casualty, Fronting, and Crop. Company distribute products through multiple channels, including retail agents, program administrators, wholesale brokers, and partnerships with other insurance companies. The companies Earthquake product generate high premium.
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.